It is unclear whether carvedilol and nebivolol will produce different effects on platelet function and prothrombotic state in heart failure (HF). Thus, we compared their effects on these functions in patients with nonischemic HF. We included 61 patients with symptomatic nonischemic HF having ejection fraction ≤40%. The patients were randomized to carvedilol (n = 31) or nebivolol (n = 30). Analyses were made at baseline, 3, and 6 months. At 6 months, mean platelet volume (MPV) was significantly lowered by both carvedilol and nebivolol therapy. However, MPV tended to be lower in the carvedilol group (7.7 ± 1.0 vs 8.0 ± 0.7 fL, P = .05). Fibrinogen and d-dimer levels were significantly decreased in but comparable in both the groups. Carvedilol and nebivolol have similar beneficial effects on platelet function and prothrombotic state in patients with nonischemic HF.
DicksteinKCohen-SolalAFilippatosG. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29(19):2388–2442.
2.
FrancisGSBenedictCJohnstonDE. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82(5):1724–1729.
3.
PackerMBristowMRCohnJN. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. carvedilol heart failure study group. N Engl J Med. 1996;334(21):1349–1355.
4.
PackerMCoatsAJFowlerMB. Carvedilol Prospective Randomized Cumulative Survival Study Group (COPERNICUS). Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344(22):1651–1658.
5.
FlatherMDShibataMCCoatsAJ. SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26(3):215–225.
6.
DoughtyRNWhiteHD. Carvedilol: use in chronic heart failure. Expert Rev Cardiovasc Ther. 2007;5(1):21–31.
7.
BristowMR. Beta-adrenergic receptor blockade in chronic heart failure. Circulation. 2000;101(5):558–569.
8.
FrishmanWHWekslerBChristodoulouJP. Reversal of abnormal platelet aggregability and change in exercise tolerance in patients with angina pectoris following oral propranolol. Circulation. 1974;50(5):887–896.
9.
WekslerBBGillickMPinkJ. Effect of propranolol on platelet function. Blood. 1977;49(2):185–196.
10.
KerryRScruttonMCWallisRB. Beta-adrenoceptor antagonists and human platelets: relationship of effects to lipid solubility. Biochem Pharmacol. 1984;33(16):2615–2622.
11.
McNeelyWGoaKL. Nebivolol in the management of essential hypertension. Drugs. 1999;57(4):633–651.
12.
FalcianiMRinaldiBD'AgostinoB. Effects of nebivolol on human platelet aggregation. J Cardiovasc Pharmacol. 2001;38(6):922–929.
13.
ParkYSchoeneNHarrisW. Mean platelet volume is an indicator of platelet activation: methodological issues. Platelets. 2002;13(5-6):301–306.
14.
GasparyanAYAyvazyanLMikhailidisDPKitasGD. Mean platelet volume: a link between thrombosis and inflammation?Curr Pharm Des. 2011;17(1):47–58.
15.
YamamotoKIkedaUFuruhashiKIrokawaMNakayamaTShimadaK. The coagulation system is activated in idiopathic cardiomyopathy. J Am Coll Cardiol. 1995;25(7):1634–1640.
16.
JungSCWilenskyRLZellerJ.Thrombin activation in dilated cardiomyopathy. J Am Coll Cardiol. 1993;21(suppl A):311A.
17.
RemmeWJ. Which beta blocker is most effective in heart failure?Cardiovasc Drugs Ther. 2010;24(4):351–358.
18.
RehsiaNSDhallaNS. Mechanisms of the beneficial effects of beta-adrenoceptor antagonists in congestive heart failure. Exp Clin Cardiol. 2010;15(4):e86–e95.
19.
Poole-WilsonPASwedbergKClelandJG. Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure. Results of the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362(9377):7–13.
20.
BakovicDPivacNEterovicD. Changes in platelet size and spleen volume in response to selective and non-selective beta-adrenoreceptor blockade in hypertensive patients. Clin Exp Pharmacol Physiol. 2009;36(4):441–446.
21.
TsiaraSElisafMJagroopIAMikhailidisDP. Platelets as predictors of vascular risk: is there a practical index of platelet activity?Clin Appl Thromb Hemost. 2003;9(3):177–190.
22.
MartinJF. Platelet heterogeneity in vascular disease. In: MartinJFTrowbridgeEA, eds. Platelet Heterogeneity: Biology and Pathology. London, UK: Springer-Verlag; 1990:205–226.
23.
MartinJFTrowbridgeEASalmonGLPlumbJ. The biological significance of platelet volume: its relationship to bleeding time, platelet thromboxane B2 production and megakaryocyte nuclear DNA concentration. Thromb Res. 1983;32(5):443–460.
24.
JakubowskiJAThompsonCBVaillancourtRValeriCRDeykinD. Arachidonic acid metabolism by platelets of differing size. Br J Haematol. 1983;53(3):503–511.
25.
GilesHSmithREMartinJF. Platelet glycoprotein IIb-IIIa and size are increased in acute myocardial infarction. Eur J Clin Invest. 1994;24(1):69–72.
26.
JagroopIAMikhailidisDP. Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol. 2003;120(1);169–170.
27.
VarolEIcliAOzaydinMErdoganDArslanA. Mean platelet volume is elevated in patients with myocardial infarction with normal coronary arteries, as in patients with myocardial infarction with obstructive coronary artery disease. Scand J Clin Lab Invest. 2009;69(5);570–574.
28.
AçıkgözNErmişNYağmurJ. The evaluation of mean platelet volume levels in patients with idiopathic and ischemic cardiomyopathy: an observational study. Anadolu Kardiyol Derg. 2011;11(7):595–599.
29.
ErtaşGKozdağGEmreEAkayYUralDHebertK. Effect of enhanced external counterpulsation treatment on mean platelet volume in patients affected by ischemic chronic heart failure. Blood Coagul Fibrinolys. 2012;23(2):127–131.
30.
CelikTYükselCUIyisoyA. Effects of nebivolol on platelet activation in hypertensive patients: a comparative study with metoprolol. Int J Cardiol. 2007;116(2):206–211.
31.
ClelandJGFSwedbergK. Carvedilol for heart failure, with care. Lancet. 1996;347(9010):1199–1201.
32.
Fibrinogen Studies Collaboration. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005;294(14):1799–1809.
33.
DaneshJWhincupPWalkerM. Fibrin d-dimer and coronary heart disease: prospective study and meta-analysis. Circulation. 2001;103(19):2323–2327.
34.
ReiningerAJ. Function of von Willebrand factor in haemostasis and thrombosis. Haemophilia. 2008;14(suppl 5):11–26.
35.
CananAHalıciogluSSGurelS. Mean platelet volume and d-dimer in patients with suspected deep venous thrombosis. J Thromb Thrombolysis. 2012;34(2):283–287.
36.
SoharaHAmitaniSKuroseMMiyaharaK. Atrial fibrillation activates platelets and coagulation in a time-dependent manner: a study of patients with paroxysmal atrial fibrillation. J Am Coll Cardiol. 1997;29(1):106–112.
